Filing search / Current reports / Brainstorm Cell Therapeutics Inc.

8-K

BCLI Brainstorm Cell Therapeutics Inc.

30 Oct 24

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

8:41am

8-K

BCLI Brainstorm Cell Therapeutics Inc.

1 Oct 24

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

4:05pm

8-K

BCLI Brainstorm Cell Therapeutics Inc.

1 Oct 24

Regulation FD Disclosure

8:00am

8-K

BCLI Brainstorm Cell Therapeutics Inc.

26 Sep 24

Other Events

4:30pm

8-K

BCLI Brainstorm Cell Therapeutics Inc.

16 Sep 24

Departure of Directors or Certain Officers

4:36pm

8-K

09l4bqcshzq05kpm

14 Aug 24

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

7:15am

8-K

gwutsk6ktp mtybgx

30 Jul 24

Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

4:05pm

8-K

wbkkupzc2jk 88p2

19 Jul 24

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

4:05pm

8-K

v2fujx 4kpj

28 Jun 24

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

7:30am

8-K

dimdpi5jat v988

26 Jun 24

Other Events

4:01pm

8-K

78v 7zu7kwae

20 Jun 24

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

5:24pm

8-K

d40nxejowrx76 ibukcn

4 Jun 24

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

6:05am

8-K

tgapr 5ioz60udpkll

3 May 24

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

4:06pm

8-K

rdlfdcles hx

16 Apr 24

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

9:31pm

8-K

zmly6 mg8ahtk4w67yc

11 Apr 24

Other Events

6:10am

8-K

1qi52whvtxr9exb6rnji

9 Apr 24

BrainStorm Cell Therapeutics Announces Agreement with FDA on a

6:05am

8-K

jcy7nd8foj

2 Apr 24

Entry into a Material Definitive Agreement

4:15pm

8-K

frg5t 9605zw

1 Apr 24

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

8:15am

8-K

nkf4g6 rhz2x

20 Dec 23

BrainStorm Issues 2023 Letter to Shareholders

5:04pm

8-K

qkdgtqd 1b5mbz

22 Nov 23

BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS

6:03am